Aberdeen Group plc and abrdn Inc. filed Amendment No. 3 to Schedule 13G with the U.S. Securities and Exchange Commission on November 2, 2026, disclosing beneficial ownership of common stock in Immunic, Inc., a clinical-stage biopharmaceutical company listed on NASDAQ:IMUX, with a triggering event date of September 30, 2026.

Key Highlights

  • Beneficial ownership: Both Aberdeen Group plc and abrdn Inc. each report aggregate beneficial ownership of 1,090,427 shares of Immunic common stock, representing 7.99% of the class.
  • Shared voting and dispositive power: Neither reporting person holds sole voting or sole dispositive power; both report shared voting power and shared dispositive power of 1,090,427 shares each.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026, according to the filing.
  • Certification date: Both Aberdeen Group plc and abrdn Inc. signed the filing on October 8, 2026, as certified by Lyn Beaton.
  • Held on behalf of clients: According to the exhibit, abrdn Inc. beneficially owns the reported shares "on behalf of our underlying clients."
  • Corporate structure: Aberdeen Group plc is identified as the parent company, abrdn Holdings Limited as the intermediate holding company, and abrdn Inc. as the subsidiary that acquired the securities.

Aberdeen Group and abrdn Inc. Disclose Combined 7.99% Position in Immunic Common Stock

According to the filing, Aberdeen Group plc, organized in the United Kingdom and headquartered at 1 George Street, Edinburgh, and its U.S.-based subsidiary abrdn Inc., headquartered at 1900 Market Street Suite 200, Philadelphia, Pennsylvania, jointly submitted Amendment No. 3 to Schedule 13G covering common stock of Immunic, Inc. (NASDAQ:IMUX). Immunic, Inc. is identified in the filing as having its principal executive offices at 1200 Avenue of the Americas, Suite 200, New York, New York 10036. The securities reported carry a par value of $0.0001 per share and are assigned CUSIP number 4525EP200.

The filing discloses that each reporting person beneficially owns 1,090,427 shares, equating to 7.99% of the outstanding class. Aberdeen Group plc is classified as a parent holding company (type HC), while abrdn Inc. is classified as a corporation and investment adviser (type CO, IA). Neither entity holds any sole voting power or sole dispositive power over the reported shares; all 1,090,427 shares are held under shared voting and shared dispositive power for each filer. The exhibit attached to the filing states that abrdn Inc. "beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G."

The certifications within the filing, signed by Lyn Beaton in her roles as Major Shareholding Reporting Analyst for Aberdeen Group plc and Senior Major Shareholding Reporting Analyst for abrdn Inc., are dated October 8, 2026. The filers certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Amendment No. 3 to Schedule 13G filed November 2, 2026 by Aberdeen Group plc and abrdn Inc. reports aggregate beneficial ownership of 1,090,427 shares, or 7.99%, of Immunic, Inc. common stock, held entirely through shared voting and dispositive power on behalf of underlying clients, with a triggering event date of September 30, 2026.